Molecular analysis of inflammatory myofibroblastic tumor (WGS and WES)

The clinical phase 2 trial EORTC 90101 “CREATE†showed high anti-tumor activity of crizotinib, the inhibitor of anaplastic lymphoma kinase (ALK)/ROS1, in patients with advanced inflammatory myofibroblastic tumor (IMFT). These findings suggested also that molecular targets beyond ALK/ROS1 contribute to the sensitivity to this kinase inhibitor. We therefore performed an in-depth molecular characterization of archival IMFT tissue, collected from patients enrolled in this trial, with the aim to identify other molecular alterations which could play a role in the response to crizotinib.EGA study EGAS00001005081